Relative to focal segmental glomerulosclerosis.
AR 113 is a nonbinding Assembly resolution recognizing focal segmental glomerulosclerosis (FSGS), a serious rare kidney disease that causes scarring in the kidneys and can progress to kidney failure. The resolution recites background information about the prevalence, severity, diagnostic delays, disproportionate impact on Black and African American communities, and the costs of FSGS to patients and the health care system. It also notes emerging research and treatment developments, including clinical trials and a first FDA-approved therapy in April 2026.
The operative provision of the resolution designates June 9, 2026, as FSGS Awareness Day in California. It also directs the Chief Clerk of the Assembly to transmit copies of the resolution to the author for distribution. As a resolution, AR 113 does not create or amend statutory law, but it formally expresses the Assembly’s support for awareness, early diagnosis, research, and access to treatment for people affected by FSGS.
AR 113 does not change California statutes, regulatory requirements, or funding levels. Its legal effect is limited to an official legislative recognition of FSGS Awareness Day and a statement of legislative concern and support. The resolution may help elevate awareness among patients, providers, researchers, and advocacy organizations, and it symbolically acknowledges the disease’s public health and equity implications.
The sentiment around the resolution appears strongly supportive and unanimous. The Assembly adopted it with 74 ayes and 0 noes, indicating no recorded opposition. The text itself is framed in sympathetic, advocacy-oriented terms, emphasizing patient hardship, the need for earlier diagnosis, and optimism about new therapies and research efforts.
There is little visible contention in the available record. Because the measure is a commemorative resolution rather than a policy bill, it does not appear to have generated debate over mandates, costs, or regulatory changes. The only potentially sensitive issues raised in the text are the disease’s disproportionate impact on minority communities, the shortage of nephrology specialists, and the role of emerging therapies and biomarkers, but these are presented as factual background rather than disputed policy questions.